Radiopharm Theranostics (RDPTF) Assets Average (2024 - 2026)

Radiopharm Theranostics (RDPTF) has reported Assets Average for 3 consecutive years, with $490209.1 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 98.95% year-over-year to $490209.1 in Q2 2026; TTM through Jun 2026 was $490209.1, a 98.95% decrease from a year earlier, with the FY2026 full-year figure at $43.4 million, down 45.19% from the prior year.
• Assets Average was $490209.1 for Q2 2026 at Radiopharm Theranostics, down from $46.5 million in the prior quarter.
• Over five years, Assets Average peaked at $46.5 million in Q2 2025 and troughed at $490209.1 in Q2 2026.
• A 3-year average of $31.2 million and a median of $46.5 million in 2024 frame the typical range for Assets Average.
• The widest YoY moves for Assets Average: up 98.95% in 2026, down 98.95% in 2026.
• Over 3 years, Assets Average stood at $46.5 million in 2024, then climbed by 0.09% to $46.5 million in 2025, then plunged by 98.95% to $490209.1 in 2026.
• The last three Assets Average figures came in at $490209.1 (Q2 2026), $46.5 million (Q2 2025), and $46.5 million (Q4 2024), per Business Quant data.